The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers
- 1 May 2006
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Psychiatry
- Vol. 19 (3) , 313-323
- https://doi.org/10.1097/01.yco.0000218604.63463.cd
Abstract
There exists a growing appreciation that, though not classical neurodegenerative disorders, severe mood disorders are associated with regional impairments of structural plasticity and cellular resilience. Exciting recent data suggest that synaptic plasticity probably is involved in mechanisms of actions of mood stabilizers and antidepressants. Notably, the extracellular signal-regulated kinase pathway is a critical ‘plasticity pathway’ in the brain. The present review summarizes neurobiological, pharmacological, and behavioral data on the role of the extracellular signal-regulated kinase pathway in regulating some of the symptoms of bipolar disorder and as a therapeutically relevant target for mood stabilizers. The extracellular signal-regulated kinase pathway is known to mediate neurotrophic actions and synaptic plasticity. Treatment with lithium and valproate activates the extracellular signal-regulated kinase pathway in cultured cells and in prefrontal cortex and hippocampus. In addition, lithium or valproate treatment promotes neurogenesis, neurite growth, and cell survival. The extracellular signal-regulated kinase pathway is also targeted by antipsychotics. Modulation of the central nervous system extracellular signal-regulated kinase pathway induces animal behavioral alterations reminiscent of manic symptoms; these complex behaviors probably depend on the effects of extracellular signal-regulated kinase on discrete brain regions and the presence of other interacting molecules. The extracellular signal-regulated kinase pathway may represent a novel target for the development of improved therapeutics for bipolar disorder.Keywords
This publication has 72 references indexed in Scilit:
- Sequential changes in BDNF mRNA expression and synaptic levels of AMPA receptor subunits in rat hippocampus after chronic antidepressant treatmentNeuropharmacology, 2005
- The ascent of mouse: advances in modelling human depression and anxietyNature Reviews Drug Discovery, 2005
- Chronic fluoxetine administration inhibits extracellular signal‐regulated kinase 1/2 phosphorylation in rat brainJournal of Neurochemistry, 2005
- Comparative analysis of the effects of four mood stabilizers in SH‐SY5Y cells and in primary neuronsBipolar Disorders, 2005
- The mood stabilizer valproic acid stimulates GABA neurogenesis from rat forebrain stem cellsJournal of Neurochemistry, 2004
- Addictive and non‐addictive drugs induce distinct and specific patterns of ERK activation in mouse brainEuropean Journal of Neuroscience, 2004
- Neuroprotective and Neurotrophic Actions of the Mood Stabilizer Lithium: Can It Be Used to Treat Neurodegenerative Diseases?Critical Reviews™ in Neurobiology, 2004
- Lithium treatment alters brain concentrations of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor in a rat model of depressionInternational Journal of Neuropsychopharmacology, 2003
- The Mood‐Stabilizing Agents Lithium and Valproate RobustlIncrease the Levels of the Neuroprotective Protein bcl‐2 in the CNSJournal of Neurochemistry, 1999
- Ras-dependent growth factor regulation of MEK kinase in PC12 cellsScience, 1994